Cerevel Therapeutics Holdings, Inc. (CERE)
| Market Cap | 4.17B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -242.65M |
| Shares Out | 148.29M |
| EPS (ttm) | -1.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,590,593 |
| Open | 28.91 |
| Previous Close | 28.63 |
| Day's Range | 27.68 - 29.41 |
| 52-Week Range | 12.50 - 46.16 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 41.31 (+46.7%) |
| Earnings Date | Aug 10, 2022 |
About CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a sel... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CERE stock is "Buy." The 12-month stock price forecast is 41.31, which is an increase of 46.75% from the latest price.
News
Cerevel Therapeutics Announces Updates to its Board of Directors
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that...
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairp...
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it ...
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chai...
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results
Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety
Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it w...
Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eigh...
3 Stocks Beating the S&P 500
Shareholders of Cerevel Therapeutics Holdings Inc ( CERE , Financial), Rexford Industrial Realty Inc. ( REXR , Financial), and Korn Ferry ( KFY , Financial) saw the value of their shares increase signif...
Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program...
Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia
Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announc...
Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strat...
Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with the potential to improve and reverse symptom...
Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates
Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it wi...
Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it w...
Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-2...
Live webcast today from 10:00 to 11:30 a.m. ET
Cerevel Therapeutics Announces Departure of CFO Kathy Yi
Current Chief Accounting Officer Mark Bodenrader named as interim CFO
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - September 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breache...
Cerevel Therapeutics to Host Virtual R&D Event on October 7
Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophr...
3 Biotech Stocks That Soared to New Heights Last Week
Find out what these industry favorites are doing to impress investors.
Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fi...
New York, New York--(Newsfile Corp. - August 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches of...
Cerevel Therapeutics Announces Redemption of Public Warrants
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience disease...